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Pathophysiology, diagnosis and treatment 
of tachycardiomyopathy
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IntroductIon
Tachycardiomyopathies (TCMP) are an important 
cause of left ventricular (LV) dysfunction that should 
be recognised by physicians as they are potentially 
reversible and have a significant impact on morbidity 
and prognosis. They are classically defined as the 
reversible impairment of ventricular function induced 
by persistent arrhythmia. However, it is becoming 
increasingly evident that they can be induced by atrial 
and ventricular ectopy promoting dyssynchrony and 
indeed the term ‘arrhythmia-induced cardiomyop-
athy’ is emerging to describe the phenomenon.1 2 
A more current proposed definition highlights aeti-
ology: ‘Atrial and/or ventricular dysfunction—sec-
ondary to rapid and/or asynchronous/irregular
 myocardial contraction, partially or completely
 reversed after treatment of the causative arrhythmia’3 
(figure 1). Two categories of the condition exist: the 
arrhythmia is the only reason for ventricular dysfunc-
tion (arrhythmia-induced), and another where the 
arrhythmia exacerbates ventricular dysfunction
 and/or worsens heart failure (HF) in a patient with 
concomitant heart disease (arrhythmia-mediated).4 
The exclusion of underlying structural heart disease 
can be challenging as current imaging techniques, 
for example, MRI cannot easily identify diffuse 
fibrosis which may itself be primary or secondary to 
the effects of arrhythmia promoting ventricular wall 
dyskinesis and stretch or valvular regurgitation.
PathoPhysIology
The mechanisms of TCMP are not fully defined 
but include subclinical ischaemia, abnormalities in 
energy metabolism, redox stress and calcium over-
load.5 6 In animal models of persistent high rate 
atrial or ventricular pacing, ventricular impairment 
is also associated with changes in myocardial elec-
trophysiology including prolongation of the action 
potential and spontaneous ventricular arrhyth-
mias. Indeed, persistent left bundle branch block 
leads to lateralisation of gap junctions promoting 
functional anisotropy and apoptosis.7 This can be 
reversed by LV pacing in HF models. These molec-
ular and cellular changes lead to abnormalities in 
chamber geometry and negative ventricular model-
ling (figure 2). It is this reversibility of ventricular 
function in these disorders that can be remedied 
by treating the primary tachycardia, which makes 
TCMP important to identify and treat promptly.
ManageMent
A timely diagnosis of TCMP is important given the 
potential for recovery with appropriate treatment. 
The possibility of TCMP should be considered when 
eliciting a history of any new diagnosis of LV dysfunc-
tion, if there is evidence of persistent or frequently 
occurring tachycardia or frequent premature ventric-
ular complexes (PVCs).8 The classic clinical presen-
tation is with symptoms and signs of congestive HF 
and dilated cardiomyopathy.9 It should be noted 
that patients may not necessarily present with an 
arrhythmia, therefore a high index of suspicion needs 
to be maintained. Patients may be diagnosed through 
echocardiography prior to the onset of clinical symp-
toms or after developing progressive HF.
It has been suggested that chronic tachycardia 
that occurs >10%–15% of the day may result in 
cardiomyopathy.2 There is no precise ventricular 
rate known to lead to TCMP, although rates above 
100 bpm are generally thought to be deleterious.5
However, as explained above, in the case of atrial 
fibrillation (AF) or PVCs, it is not only a high heart rate 
(HR), but also asynchronous myocardial contraction, 
that can lead to LV dysfunction.The resting HR may 
not give an indication of the mean HR, as there may 
be an exaggerated response to exertion, so ambulatory 
monitoring is important for diagnosis as well as identi-
fying subclinical arrhythmias.
Other factors that point to a diagnosis of TCMP 
include: (i) evidence of a previously normal ejec-
tion fraction (EF) and a degree of LV dysfunc-
tion out of proportion to other comorbidities, 
(ii) no other cause of non-ischaemic cardiomy-
opathy found (eg, hypertension, alcohol or drug 
use, stress, etc), (iii) absence of left ventricular 
hypertrophy, (iv) relatively normal LV dimensions 
(LV end-diastolic dimension below 5.5 cm), (v) 
recovery of LV function after control of tachy-
cardia (by rate control, cardioversion or radiof-
requency ablation within 1–6 months) and (vi) 
rapid decline in LV ejection fraction (LVEF) 
following recurrence of tachycardia in a patient 
with recovered LV function after previous control 
of tachycardia.
While the classic definition of TCMP refers to 
an impairment of LV function in the absence of 
structural heart disease, in practice patients with 
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 ► Understand the pathophysiology
 ► Determine treatment strategies to restore 
left ventricular function
 ► The role of TCMP in non-responders to cardiac 
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pre-existing ventricular dysfunction often deterio-
rate in the face of an uncontrolled tachycardia, and 
therefore the role of the tachycardia should be taken 
into account. It may be difficult in such circum-
stances to distinguish whether the arrhythmia or 
the cardiomyopathy is the primary driver. Cardiac 
imaging provides important information in TCMP 
to identify underlying structural disease—patients 
initially have smaller LV end-diastolic diameters 
and LV volume adjusted for body surface area 
and LV mass compared with patients with idio-
pathic dilated cardiomyopathy.10 The presence of 
gadolinium late enhancement can be an indicator 
of structural pathology pointing to a reduced like-
lihood to response in the context of PVC abla-
tion.11 In an electro-anatomical mapping study of 
PVC cases, patients with irreversible cardiomyop-
athy had greater areas of low amplitude signals, a 
reduced unipolar voltage area ≥32% of LV endo-
cardium predicted the irreversibility of cardiomy-
opathy with >95% sensitivity and specificity, but 
prospective validation is lacking.12
Serial assessment of the N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) ratio (NT-BNP 
at baseline/NT-BNP during follow-up) can differ-
entiate TCMP from irreversible dilated cardiomy-
opathy. A prompt decline in NT-proBNP levels, 
after direct currect (DC) cardioversion of AF was 
associated with reversible cardiomyopathy with an 
accuracy of 90% in one series.13
The diagnosis of TCMP may be evident only 
after restoration and maintenance of sinus 
rhythm, or after aggressive rate control meaning a 
two-pronged approach to treat the arrhythmia and 
cardiac dysfunction is required.
Once the diagnosis of TCMP has been made, 
many authors advocate a pro-active treatment 
approach. The exact strategy employed is depen-
dent on the causative arrhythmia, as detailed below, 
where either a rate or rhythm control strategy may 
be more appropriate.8 Potentially curative ablation 
is often the treatment of choice, especially for SVTs, 
and also AF, ventricular tachycardia (VT) and PVCs.
arrhythMIas
The first report of a man with dilated cardiomy-
opathy resulting from rapid AF was by Gossage 
in 1913.14 Since then, numerous studies have 
demonstrated that multiple forms of tachycardia 
may result in TCMP; these include AF, atrial 
flutter, incessant SVT, VT and PVCs15–19 (figure 1). 
Figure 1 Arrhythmias leading to left ventricular dysfunction. AF, atrial fibrillation; LBBB, left bundle branch block; PVCs, premature ventricular 
complexes; RBBB, right bundle branch block; RV, right ventricular; SVT, supraventricular tachycardia.
Figure 2 Mechanisms of tachycardiomyopathy (TCMP). The molecular, microscopic 
and structural effects of TCMP.
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Restoring sinus rhythm, controlling ventricular 
response and decreasing the burden of ventricular 
ectopics can all lead to improvement in LV func-
tion and symptoms of HF. TCMP may occur at any 
age, with cases reported in utero20 and in infants 
and children,21–23 as well as in adults (figure 3 
illustrates clinical examples). The true incidence is 
unknown as TCMP is a diagnosis of exclusion, and 
is therefore likely to be under-recognised in clin-
ical practice—reported series describe incidences 
of 8%–28% in focal/ectopic atrial tachycardias and 
9%–34% for ventricular ectopy and non-sustained 
VT.11 18 24–27 Most reports in the literature involve 
small retrospective series or individual case reports.
suPraventrIcular arrhythMIas
Whipple et al28 were the first to demonstrate 
that rapid atrial pacing can induce impairment 
in ventricular function. Persistent AF is the most 
studied arrhythmia associated with TCMP, as it is 
chronic and has a high prevalence. Persistent AF is 
known to be associated with an increased risk of 
HF. LV function improves with any of a number 
of AF treatment strategies, whether that be rate 
control through medication or a ‘pace and ablate’ 
procedure (AVN ablation and single chamber VVI 
pacing), or rhythm control with cardioversion, 
anti-arrhythmic drugs or catheter ablation.29–33 
Dissecting whether the LV impairment is due to 
underlying structural heart disease or the lack of 
atrial transport and rapid, irregular ventricular 
rates in their own right is difficult.32 34 A ‘pace and 
ablate’ procedure improves LV function even if 
the ventricular response was well controlled prior, 
showing that regularity is likely to be important as 
well as rate.35 However, this approach results in LV 
dysynchrony and is usually a last resort reserved for 
elderly patients intolerant of medications.
Randomised studies of AF ablation do demon-
strate positive effects on LV remodelling once sinus 
rhythm is re-established over and above pure rate 
control. Restoration of sinus rhythm with pulmo-
nary vein isolation was superior to AV node abla-
tion and cardiac resynchronisation (CRT), where 
the effects of single chamber VVI pacing are mini-
mised (figure 4).36 37 In the recent AATAC-AF trial 
which randomised 203 persistent AF patients with 
HF and cardiomyopathy (LVEF<40%) to either 
amiodarone or catheter ablation, 70% of patients 
in the ablation arm were free of AT/AF (vs 34% in 
the amiodarone arm (p<0.001)) and had significant 
improvements in mortality, hospitalisation rates and 
quality of life. LVEF improved 9.6%±7.4% in the 
Figure 3 Case vignettes. (1) A man aged 33 years presented complaining of a pulsation in his neck but no other symptoms. (A) MRI demonstrated 
a markedly dilated left ventricle (LV) and severely impaired biventricular function with extensive mid-wall fibrosis in keeping with a dilated 
cardiomyopathy. Coronary angiography was normal. (B) ECG demonstrated an incessant idiopathic ventricular rhythm. Electrophysiological studies 
(EPS) demonstrated a focal source at the right ventricular inflow (note the left bundle branch block pattern with Q waves in the inferior leads 
indicative of this focus). (C) Ablation at this location terminated the tachycardia and at follow-up his LV function had normalised. (2) A female aged 
25 years suffered a cardiac arrest post partum, having had a 2-week preceding history of incessant palpitations. (D) ECG demonstrated a regular 
narrow complex tachycardia, which was terminated with a synchronised shock. (E) Echocardiogram demonstrated a dilated and severely impaired 
LV. (F) EPS demonstrated AVNRT with 2:1 and 1:1 conduction. Slow pathway modification terminated the tachycardia and at follow-up LV function 
has normalised.  (3) A man aged 54 years presented with a 3-month history of rapidly deteriorating breathlessness and palpitations. (G) MRI 
demonstrated dilated and severely impaired LV (see supplementary file video 1). (H) ECG demonstrated AF with a fast ventricular response. He was 
rate-controlled with beta-blockers and underwent urgent ablation comprising bilateral wide area circumferential ablation, roof line and mitral isthmus 
line. He has subsequently maintained sinus rhythm and his LV function has gradually normalised (I) (see online supplementary video 2). 
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ablation arm versus 4.2%±6.2% in the amiodarone 
arm (p<0.01).38 This is supported by a systematic 
review of 19 studies (914 patients) evaluating AF 
ablation in patients with concomitant LV dysfunc-
tion where LVEF increased by 13.3% (95% CI 11% 
to 16%), with 57% maintenance sinus rhythm, after 
a single procedure and 82% after >1 procedure 
and/or use of anti-arrhythmic drugs.39
This highlights that restoration of sinus rhythm 
is an important determinant of recovery of LV 
function if it can be achieved long term. The 
patients most likely to respond to this ‘rhythm 
control’ ablation approach are those with no 
evidence of myocardial abnormalities on advanced 
imaging and an otherwise normal ECG without 
significant conduction/repolarisation changes. 
Patients with a short history of symptoms coin-
ciding with the onset of AF appear to have the 
highest chance of success using this approach, 
although large randomised controlled trials are 
required to address this formally with prolonged 
follow-up, for example, Catheter Ablation vs 
Anti-arrhythmic Drug Therapy for Atrial Fibril-
lation (CABANA) and Early Treatment of Atrial 
Fibrillation for Stroke Prevention (EAST) trials. 
Once advanced structural remodelling in the atria 
has occurred (significant LA dilation), the chances 
of long-term ablation success decline.
Atrial flutter is another common cause of TCMP. 
One study found that there was LV dysfunction in 
25% of patients presenting in atrial flutter, and 57% 
of cases improved after ablation.16 Incessant atrial 
tachycardia is a relatively uncommon arrhythmia, 
but is a well-recognised cause of TCMP. It is usually 
caused by an automatic focus.40–43 Treatment of the 
atrial tachycardia by surgery (historical reports26–28 
or catheter ablation44 45 will normalise LV func-
tion. Although the ChadsVasc score is established 
for anticoagulation decision making in AF and 
atrial flutter, given the fact that focal AT in TCMP 
can degenerate into AF or may promote throm-
bosis in the dilated ventricle/atrial appendage, some 
consideration should be given to anticoagulation in 
this context, although formal evidence is lacking at 
present. 
Re-entrant SVTs including atrioventricular nodal 
reentrant tachycardia (AVNRT) and  atrioven-
tricular reentrant tachycardia (AVRT) are usually 
paroxysmal and are therefore a rare cause of 
TCMP.46–49 One well-known example, however, 
is persistent junctional reciprocating tachycardia, 
which is a form of incessant AVRT, most common 
in paediatric cases. This usually involves a slowly 
conducting septal accessory pathway, but the 
pathway may occasionally be found elsewhere on 
either annulus. Ectopic atrial tachycardias are the 
the most common cause of TCMP in children.
A non-re-entrant form of AV nodal tachycardia 
may occasionally cause TCMP when a single sinus 
beat leads to two ventricular depolarisations with 
Figure 4 Effect of pulmonary vein isolation (PVI) vs AVN ablation+cardiac resynchronisation on left ventricular function and exercise tolerance in 
the Pulmonary Vein Antrum Isolation versus AV Node Ablation with Bi-Ventricular Pacing for Treatment of Atrial Fibrillation in Patients with Congestive 
Heart Failure (PABA CHF) trial. From Khan et al.37
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simultaneous antegrade conduction through fast 
and slow AV nodal pathways.50 If frequent enough 
this may lead to an incessant 1:2 tachycardia. In a 
review of 44 such cases described between 1970 
and 2010, 8 had reduced LV function as a result.51 
In all cases of SVT-mediated TCMP, treatment of 
the arrhythmia with drugs52 surgery45 46 or catheter 
ablation47–49 will reverse the LV dysfunction
ventrIcular arrhythMIas
Ventricular arrhythmias causing TCMP are gener-
ally idiopathic in nature, as otherwise they may be 
classified as being part of the disease process leading 
to both arrhythmias and LV dysfunction. Thus, 
sustained monomorphic VT rarely causes TCMP, as 
it is more often associated with pre-existing struc-
tural heart disease. Idiopathic VT, if persistent or 
sufficiently frequent, may result in reversible LV 
dysfunction.53–55 It most often arises from the right 
ventricular outflow tract. One study has shown that 
11% of patients presenting with frequent PVCs also 
had sustained monomorphic VT, and 7% of these 
had TCMP. 56 LV dysfunction will usually normalise 
following ablation of the ectopic focus.54 55 57
eFFects oF Pvcs on lv FunctIon and 
eFFIcacy oF crt
Another area of much investigation and debate is 
the role of PVCs in promoting LV dysfunction. 
This issue has been addressed by several studies 
examining PVC burden and the role of ablation 
with LV impairment ranging from PVC frequency 
thresholds of 5–30 000 beats in 24 hours.13 14 
A high PVC burden has been variably defined as 
ranging from >10 000 to 25 000 PVCs/day and as 
>10% to 24% of total heartbeats/day.58–60 There 
appears to be a threshold burden of ~10 000 PVCs/
day for developing TCMP. A recent paper iden-
tified a threshold of 13%, which equates to a 
burden of approximately 30 000/24 hour (figure 5). 
Interestingly, ablation of >13% baseline PVC 
burden had 100% sensitivity and 85% specificity to 
predict an absolute increase in LVEF independent 
of evidence of structural heart disease on imaging.61 
A number of studies have examined factors most 
likely to result in LV dysfunction including lack of 
symptoms, male sex, increased body mass index, 
higher PVC coupling interval dispersion, interpo-
lated PVCs and presence of retrograde P waves. A 
QRS width >150 ms or epicardial origin appears 
a significant determinant probably because of the 
greater degree of dyssynchrony it promotes62 63 (see 
figure 3B—right ventricular inflow tract PVCs).
The question of whether to ablate asymptom-
atic monomorphic PVCs when the burden is high 
should be discussed carefully with the patient as 
PVC ablation particularly in the right ventricular 
outflow tract does carry a small but important 
risk of tamponade (<1%) and even death. Since 
PVC ablation restores normal LV function in the 
structurally normal heart, a pragmatic approach 
in these cases is simply to monitor the patient for 
signs of LV impairment and only consider ablation 
should this be the case. This is because isolated 
PVCs have an excellent prognosis in the normal 
hearts with preserved function anyway, so there is 
no reason to intervene unless significant dysfunc-
tion develops. Recently, Bhushan and Asirvatham 
have proposed criteria regarding PVC-induced 
cardiomyopathy. They suggest that otherwise 
young healthy individuals, without abnormal 
cardiovascular substrate having over 20 000 PVCs 
per day, no more than two PVC morphologies, 
PVCs originating from outflow tracts or from 
the fascicles and with preserved myocardial wall 
thickness are the best candidates for presumption 
of a PVC-induced cardiomyopathy diagnosis.5 
The most prominent predictor of cardiomyopathy 
in patients with frequent PVCs appears to be the 
daily burden of PVCs. Ventricular function can 
Figure 5 Premature ventricular complex (PVC) burden threshold likely to identify cases most likely to ablation to improve left ventricular function. A 
13% baseline PVC burden had 100% sensitivity and 85% specificity to predict an absolute increase ≥5% in LV ejection fraction (LVEF) after sustained 
successful ablation (SSA). From Penela et al.61
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improve if the PVC burden is reduced to <5000/
day.64 This is an important target when elimina-
tion of all PVCs may not be possible, especially in 
the context of multifocal PVCs; overall, the effi-
cacy of ablation is 70%–90%.
The role of PVCs in promoting LV impairment 
is becoming evident in determining the response to 
CRT.65 Burdens as low as >0.1% result in signif-
icant reductions in response to CRT and clin-
ical outcomes.65 66 In the Multicenter Automatic 
Defibrillator Implantation Trial With Cardiac 
Resynchronization Therapy trial, patients with as 
little as >0.1% ectopic beats had a lower probability 
of >97% CRT pacing and significantly less reverse 
remodelling (per cent reduction in LVESV 31±15%) 
than patients with <0.1% ectopic beats (per cent 
reduction in LVESV 39±14%; p<0.001).65 The 
risk of HF/death and ventricular arrhythmias was 
increased significantly in those with 0.1%–1.5% 
ectopic beats (HR: 3.13 and 1.84, respectively) 
and for >1.5% ectopic beats (HR: 2.38 and 2.74, 
respectively) (figure 6). This raises the question as 
to whether an intervention to prevent the ectopy 
is beneficial. A recent trial examining the effect of 
PVC ablation on outcomes identified a threshold 
of 22% ectopy likely to improve LV function with 
successful ablation in this context.67 It is important 
to emphasise that this strategy is best considered 
when there is a predominant (ideally single) PVC 
morphology.
tIMe course 
The time course of TCMP has mostly been studied 
in animal models with rapid pacing. Haemody-
namic abnormalities may be seen 24 hours after 
the onset of rapid pacing. After 1 week, there will 
be increased filling pressures, increased pulmonary 
artery pressures and decreased systemic arterial 
pressures. Up to 3–5 weeks, the cardiac output, 
EF, cardiac volume continue to worsen.68–71 Time 
to recovery from TCMP is thought to be rate and 
duration dependent. Often patients do not seek 
medical attention until they have had symptoms 
of heart failure for some time. In animal models, 
if rapid pacing is stopped, changes in filling pres-
sures, cardiac output and systemic vascular resis-
tance are usually reversible. EF improvement 
may take several weeks to normalise72 73 and 
contractile dysfunction can be seen up to 4 weeks 
later.74 End-systolic and end-diastolic volumes 
may still be elevated 12 weeks after cessation 
of pacing.69 71 73 75 Occasionally, EF may not 
normalise and some abnormalities in contractile 
function may persist.69 73 76
Similarly in humans, there is usually rapid clin-
ical improvement. By 3 months after successful 
treatment of tachycardia whether by rhythm 
or rate control, nearly complete recovery of 
symptoms and LV contractility is generally 
observed.10 77 However, some more recent studies 
have not confirmed such significant improve-
ments in New York Heart Association class or 
objective measures of cardiac function.33 78 In 
others, despite normalisation of EF, persistent LV 
remodelling has been demonstrated with elevated 
LV dimensions and volumes.79 This would suggest 
that HF therapy should be continued even once 
EF has recovered. Furthermore, LV hypertrophy 
may also develop after cessation of pacing in 
animal models through a postpacing response of 
myocytes to hypertrophic triggers, although the 
exact mechanisms are not well understood5 74 80 
and this has not been seen reproducibly in humans.
recurrence
There is evidence to suggest that recurrent tachy-
cardia in patients who have previously had TCMP, 
may result in a faster and more severe onset of 
TCMP than the initial presentation. In one study 
of 24 patients with TCMP, 5 had recurrent tachy-
cardia associated with a rapid drop in EF and symp-
toms of clinical HF occurring within 6 months81; 
other small case series have reported similar find-
ings.82 83 This suggests that there must be some 
structural cardiac abnormalities that persist after 
an apparent recovery in function. Therefore, 
maintenance of an HF treatment regimen after 
normalisation of EF, and continued monitoring of 
patients for recurrence of arrhythmia is a prudent 
strategy.84
sudden death
There is very little information available regarding 
the risk of sudden death in TCMP. HF, what-
ever the aetiology, leads to an arrhythmogenic 
substrate with repolarisation abnormalities impli-
cated in leading to ventricular arrhythmias. Most 
studies have employed animal models, which have 
given conflicting results. A porcine model shows 
prolonged repolarisation, but with no deaths85; 
a canine model with repolarisation abnormali-
ties demonstrated polymorphic VT as clinical HF 
worsened.86
A contentious issue is whether patients with 
resolved TCMP and normal LV function continue 
Figure 6 Premature ventricular complex burden effects on cardiac resynchronisation 
response. From Ruwald et al.65
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to have increased risk of lethal arrhythmia due to 
pathological remodelling. Evidence is scarce, with 
one case report of three patients with AF-related 
TCMP where EF had normalised with treatment. 
They all died suddenly months to years later, with 
normal EF and no symptoms of HF or recurrent 
tachycardia.81 One further patient with atrial 
flutter and TCMP who recovered with rate control, 
died suddenly 4 years later with no preceding 
symptoms.82
Future dIrectIons
Although the aetiology of TCMP is well defined, 
there remain a number of unanswered questions in 
terms of identifying patients most at risk and the 
timing of any intervention. Furthermore, there 
may be specific genetic, molecular and structural 
features which identify patients at greatest risk that 
require further investigation. Also a proportion of 
patients do not necessarily fully respond to rhythm 
control or remain at risk of lethal arrhythmia. Iden-
tification of specific biomarkers to identify these 
individuals should be pursued through genetic, 
molecular profiling and imaging strategies.
conclusIon
There is a wide range of causative arrhythmias, clin-
ical presentations and natural histories for TCMP. 
The diagnosis of TCMP is difficult and a high index 
of suspicion is required. Given the potential for 
recovery with appropriate treatment, a proactive 
approach is recommended, whether that be rate or 
rhythm control. With advances in cardiac imaging 
and ablation techniques, it may be possible to iden-
tify patients with reversible causes of cardiomyop-
athy early in the disease process with those most 
likely to respond to rhythm control. In the mean-
time, a strategy attempting to minimise arrhythmia 
Key messages
 ► Always consider an arrhythmic aetiology as a factor contributing to cardiac 
dysfunction, especially in the absence of overt ventricular structural 
abnormalities.
 ► Seriously consider an early rhythm control strategy and the possibility of 
ablation in atrial fibrillation cases with tachycardiomyopathy.
 ► Carefully review ventricular ectopic burden and morphology in 
cardiomyopathy cases with a view to electrophysiological assessment for 
ablation.
 ► Consider ablation of monomorphic ectopics in cardiac resynchronisation 
non-responders if receiving <97% biventricular pacing due to ventricular 
ectopy.
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Figure 7 Outline of management strategy for tachycardiomyopathy. Heart failure (HF) and prevention of sudden cardiac death in structural heart 
disease management should be followed as per the European Guidelines. (Adapted from Gopinathannair et al4; see European Guidelines on HF 
and prevention of sudden cardiac death (SCD)84). AF, atrial fibrillation; LV, left ventricular; PVC, premature ventricular complex; SVT, supraventricular 
tachycardia; TC, tachycardia.
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burden to assess the response even if short term, 
for example, DC cardioversion for AF with anti-ar-
rhythmic therapy gives a pragmatic approach to 
identify such cases.
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